Indication
HER2-Low Breast Cancer
3 clinical trials
5 products
1 drug
Clinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2Status: Recruiting, Estimated PCD: 2027-04-01
Product
XMT-2056Clinical trial
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform TrialStatus: Recruiting, Estimated PCD: 2026-12-30
Product
ALX148Product
Fam-Trastuzumab DeruxtecanProduct
ZanidatamabDrug
TucatinibClinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib TrialStatus: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazine